MCID: FBR019
MIFTS: 44

Fibromatosis

Categories: Cancer diseases, Rare diseases

Aliases & Classifications for Fibromatosis

MalaCards integrated aliases for Fibromatosis:

Name: Fibromatosis 52 54 17 71

Classifications:



External Ids:

UMLS 71 C0016048

Summaries for Fibromatosis

NIH Rare Diseases : 52 Fibromatosis refers to a group of conditions characterized by overgrowths of skin and connective tissue called fibromas. These fibromas are usually benign (non-cancerous). Fibromatosis can be classified by a person's age or by the location of the fibromas. The cause of fibromatosis is often unknown, and treatment depends on the individual disease.

MalaCards based summary : Fibromatosis is related to gingival fibromatosis and desmoid disease, hereditary. An important gene associated with Fibromatosis is SOS1 (SOS Ras/Rac Guanine Nucleotide Exchange Factor 1), and among its related pathways/superpathways are Cytoskeleton remodeling Regulation of actin cytoskeleton by Rho GTPases and Colorectal Cancer Metastasis. The drugs Sorafenib and Protein Kinase Inhibitors have been mentioned in the context of this disorder. Affiliated tissues include breast, bone and skin, and related phenotypes are cardiovascular system and cellular

Wikipedia : 74 The term fibromatosis refers to a group of soft tissue tumors which have certain characteristics in... more...

Related Diseases for Fibromatosis

Diseases related to Fibromatosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 477)
# Related Disease Score Top Affiliating Genes
1 gingival fibromatosis 33.7 SOS1 REST GINGF3
2 desmoid disease, hereditary 33.6 CTNNB1 APC
3 infantile digital fibromatosis 33.5 VIM DES
4 desmoid tumor 32.6 DES CTNNB1 APC ACTC1
5 pseudosarcomatous fibromatosis 32.4 VIM DES CTNNB1 ACTC1
6 familial adenomatous polyposis 1 30.8 CTNNB1 APC
7 rare tumor 30.5 DES ACTC1
8 gingival hypertrophy 30.5 VIM SOS1 ANTXR2
9 connective tissue benign neoplasm 30.1 CTNNB1 APC
10 fibrosarcoma 30.0 VIM DES ACTC1
11 fibroblastic rheumatism 29.8 DES ACTC1
12 fasciitis 29.7 VIM DES ACTC1
13 fibroma 29.6 VIM DES CTNNB1 ACTC1
14 infantile myofibromatosis 29.5 VIM DES ACTC1
15 leiomyoma 29.5 VIM DES ACTC1
16 non-langerhans-cell histiocytosis 29.5 DES ACTC1
17 spindle cell carcinoma 29.5 VIM DES ACTC1
18 congenital fibrosarcoma 29.3 VIM DES ACTC1
19 fibrous histiocytoma 29.3 VIM DES ACTC1
20 spindle cell sarcoma 29.3 VIM DES ACTC1
21 leiomyosarcoma 29.3 VIM DES ACTC1
22 perineurioma 29.1 VIM ACTC1
23 neurilemmoma 29.1 VIM DES ACTC1
24 dermatofibrosarcoma protuberans 29.0 VIM DES ACTC1
25 malignant fibroxanthoma 29.0 VIM DES ACTC1
26 sarcoma, synovial 29.0 VIM DES CTNNB1
27 hemangiopericytoma, malignant 28.9 VIM DES ACTC1
28 teratoma 28.9 VIM CTNNB1 ACTC1
29 liposarcoma 28.8 VIM DES CTNNB1
30 inflammatory myofibroblastic tumor 28.8 VIM DES ACTC1
31 gastrointestinal stromal tumor 28.8 VIM DES ACTC1
32 granular cell tumor 28.8 VIM DES
33 mesothelioma, malignant 28.7 VIM DES CTNNB1
34 reticulum cell sarcoma 28.7 VIM DES ACTC1
35 adenosarcoma 28.7 VIM DES ACTC1
36 sarcomatoid mesothelioma 28.7 VIM DES ACTC1
37 cutaneous fibrous histiocytoma 28.7 VIM DES ACTC1
38 glomus tumor 28.6 VIM DES ACTC1
39 smooth muscle tumor 28.6 VIM DES ACTC1
40 giant cell tumor 28.6 VIM DES ACTC1
41 endometrial stromal sarcoma 28.5 VIM DES ACTC1
42 medulloblastoma 27.4 VIM REST DES CTNNB1 APC ACTC1
43 hyaline fibromatosis syndrome 12.8
44 fibromatosis, gingival, 1 12.8
45 fibromatosis, gingival, 2 12.6
46 fibromatosis, gingival, 4 12.6
47 fibromatosis, gingival, 5 12.6
48 fibromatosis, gingival, with progressive deafness 12.6
49 plantar fascial fibromatosis 12.5
50 fibromatosis, gingival, 3 12.4

Graphical network of the top 20 diseases related to Fibromatosis:



Diseases related to Fibromatosis

Symptoms & Phenotypes for Fibromatosis

MGI Mouse Phenotypes related to Fibromatosis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.76 ACTC1 ANTXR2 APC CTNNB1 DES REST
2 cellular MP:0005384 9.56 ACTC1 ANTXR2 APC CTNNB1 DES REST
3 muscle MP:0005369 9.1 ACTC1 APC CTNNB1 DES SOS1 VIM

Drugs & Therapeutics for Fibromatosis

Drugs for Fibromatosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 85)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sorafenib Approved, Investigational Phase 3 284461-73-0 216239 406563
2 Protein Kinase Inhibitors Phase 3
3
Toremifene Approved, Investigational Phase 2 89778-26-7 3005573
4
Sodium citrate Approved, Investigational Phase 2 68-04-2
5
Sulindac Approved, Investigational Phase 2 38194-50-2 5352 1548887
6
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
7
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 126941
8
leucovorin Approved Phase 2 58-05-9 6006 143
9
Vinblastine Approved Phase 2 865-21-4 13342 241903
10
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
11
Aminolevulinic acid Approved Phase 2 106-60-5 137
12
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
13
nivolumab Approved Phase 2 946414-94-4
14
Ipilimumab Approved Phase 2 477202-00-9
15
Sirolimus Approved, Investigational Phase 1, Phase 2 53123-88-9 5284616 6436030 46835353
16
Everolimus Approved Phase 1, Phase 2 159351-69-6 6442177 70789204
17
Miconazole Approved, Investigational, Vet_approved Phase 1, Phase 2 22916-47-8 4189
18
Guaifenesin Approved, Investigational, Vet_approved Phase 2 93-14-1 3516
19
Calcium Approved, Nutraceutical Phase 2 7440-70-2 271
20
Citric acid Approved, Nutraceutical, Vet_approved Phase 2 77-92-9 311
21
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
22
Imidazole Experimental, Investigational Phase 2 288-32-4 795
23 Calcium, Dietary Phase 2
24 Citrate Phase 2
25 Anticoagulants Phase 2
26 Chelating Agents Phase 2
27 Angiogenesis Inhibitors Phase 2
28 Vitamin B Complex Phase 2
29 Folic Acid Antagonists Phase 2
30 Dermatologic Agents Phase 2
31 Folate Phase 2
32 Vitamin B9 Phase 2
33 Antimetabolites Phase 2
34 Antimitotic Agents Phase 2
35 Topoisomerase Inhibitors Phase 2
36
Liposomal doxorubicin Phase 2 31703
37 Anesthetics Phase 2
38 Pharmaceutical Solutions Phase 2
39 Photosensitizing Agents Phase 2
40 Albumin-Bound Paclitaxel Phase 2
41 Antineoplastic Agents, Immunological Phase 2
42 Antibodies, Monoclonal Phase 2
43 Antibodies Phase 2
44 Immunoglobulins Phase 2
45 Imatinib Mesylate Phase 2 220127-57-1 123596
46 Immunosuppressive Agents Phase 1, Phase 2
47 Immunologic Factors Phase 1, Phase 2
48 Anti-Bacterial Agents Phase 1, Phase 2
49 Antibiotics, Antitubercular Phase 1, Phase 2
50 Anti-Infective Agents Phase 1, Phase 2

Interventional clinical trials:

(show all 48)
# Name Status NCT ID Phase Drugs
1 Prospective Trial Comparing the Performance Profiles of Two Non-Cross-Linked Porcine Dermal Matrices in Abdominal Wall Reconstruction Recruiting NCT02228889 Phase 4
2 A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Nirogacestat Versus Placebo in Adult Patients With Progressing Desmoid Tumors/Aggressive Fibromatosis (DT/AF) Recruiting NCT03785964 Phase 3 Nirogacestat oral tablet;Placebo Oral Tablet
3 Ledderhose Disease: Radiotherapy or Not? A Randomised, Multicentre, Prospective, Double Blind Phase III Trial Investigating the Effect of Radiotherapy on Patients With Ledderhose Disease Recruiting NCT03507010 Phase 3
4 A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF) Active, not recruiting NCT02066181 Phase 3 Sorafenib Tosylate
5 Toremifene in Desmoid Tumor: Prospective Clinical Trial and Identification of Potential Molecular Targets Unknown status NCT02353429 Phase 2 Toremifene
6 Dupuytren's Disease and Extracorporeal Shockwave Therapy (DupuyShock-2010) - a Randomized Trial Unknown status NCT01184586 Phase 2
7 Phase II Study to Evaluate Glivec (Imatinib Mesylate) to Induce Progression Arrest in Aggressive Fibromatosis / Desmoid Tumors Not Amenable to Surgical Resection With R0 Intent or Accompanied by Unacceptable Function Loss Completed NCT01137916 Phase 2 Imatinib
8 A Phase II Trial of Imatinib for Patients With Aggressive Desmoid Tumor (Aggressive Fibromatosis) Completed NCT02495519 Phase 2 Imatinib
9 Multicentric Phase I/II Study Evaluating the Efficacy and Toxicity of Imatinib in Adult Patients With Aggressive Fibromatosis That Cannot be Treated by Surgery or Curative Radiotherapy Completed NCT00287846 Phase 1, Phase 2 imatinib mesylate
10 Vinblastine and Methotrexate in Children With Desmoid Tumor (Aggressive Fibromatosis) Which is Recurrent or Not Amenable to Surgical Resection or Irradiation - A Pediatric Oncology Group Phase II Study Completed NCT00003019 Phase 2 methotrexate;vinblastine sulfate
11 Phase II Pilot Study Of Moderate Dose Radiotherapy For Inoperable Aggressive Fibromatoses Completed NCT00030680 Phase 2
12 Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases Completed NCT00154388 Phase 2 Imatinib mesylate
13 A Phase II Study of Sulindac and Tamoxifen in Patients With Desmoid Tumors That Are Recurrent or Not Amenable to Standard Therapy Completed NCT00068419 Phase 2 tamoxifen citrate;sulindac
14 PHASE II STUDY OF THE SAFETY AND EFFICACY OF TOREMIFENE IN THE THERAPY OF DESMOID TUMORS Completed NCT00002595 Phase 2 toremifene
15 A Multicenter Phase II Study of Continuous Dosing of Sunitinib (Sutent®, SU11248) in Non-GIST Sarcomas Completed NCT00474994 Phase 2 sunitinib malate
16 Vinblastine and Methotrexate in Children With Multivessel Pulmonary Vein Stenosis-A Phase II Study Completed NCT00215046 Phase 2 Vinblastine;Methotrexate
17 Doxorubicin Eluting Intra-arterial Embolization for Aggressive Desmoid Fibromatosis Recruiting NCT03966742 Phase 2
18 A Phase 1b/2a, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Vactosertib in Combination With Imatinib in Patients With Advanced Desmoid Tumor (Aggressive Fibromatosis) Recruiting NCT03802084 Phase 1, Phase 2 vactosertib/imatinib combination
19 A PHASE 2, SINGLE CENTRE, SINGLE ARM STUDY TO DETERMINE THE EFFICACY AND SAFETY OF 5- ALA POHOTODYNAMIC THERAPY AS ADJUVANT THERAPY AFTER SURGICAL DISSECTION IN PATIENTS WITH DESMOID TUMORS. Recruiting NCT01898416 Phase 2 5-AMINOLEVULINIC ACID (5-ALA), is a non fluorescent prodrug.
20 PAZOPANIB Efficacy and Tolerance in Desmoids Tumors : Phase 2 Clinical Trial Recruiting NCT01876082 Phase 2 PAZOPANIB treatment;Active Comparator: Vinblastine and Methotrexate
21 Phase II Trial of Nab-paclitaxel for the Treatment of Desmoid Tumors and Multiply Relapsed/Refractory Desmoplastic Small Round Cell Tumors and Ewing Sarcoma Recruiting NCT03275818 Phase 2 nab paclitaxel
22 DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors Recruiting NCT02834013 Phase 2
23 Open-label Trial of Imatinib in Patients With Desmoid Tumor and Chondrosarcoma Active, not recruiting NCT00928525 Phase 2 Imatinib Mesylate
24 Phase II Trial of the Gamma-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors/Aggressive Fibromatosis Active, not recruiting NCT01981551 Phase 2 PF-03084014
25 A Pilot Study Evaluating the Use of mTor Inhibitor Sirolimus in Children and Young Adults With Desmoid-Type Fibromatosis Active, not recruiting NCT01265030 Phase 1, Phase 2 Sirolimus
26 A Safety, Pharmacokinetic and Efficacy Study of a y-Secretase Inhibitor, Nirogacestat (PF-03084014), in Children and Adolescents With Progressive, Surgically Unresectable Desmoid Tumors Not yet recruiting NCT04195399 Phase 2 Nirogacestat
27 Effect of Hydroxyurea as Treatment for Primary Desmoid Tumors in Adults and Children (CHP-914) Withdrawn NCT00978146 Phase 2 Hydroxyurea
28 A Pilot Study of Intralesional Injection of Triamcinolone Acetonide for Desmoid Tumors Recruiting NCT03627741 Phase 1 Triamcinolone Acetonide
29 Phase 1 Trial of BC2059 (Tegavivint) in Patients With Unresectable Desmoid Tumor Recruiting NCT03459469 Phase 1 Tegavivint
30 Safety and Feasibility Study of Using MR-guided High Intensity Focused Ultrasound (HIFU) for the Ablation of Relapsed or Refractory Pediatric Solid Tumors Recruiting NCT02076906 Phase 1
31 Phase I Trial of Z-Endoxifen in Adults With Refractory Hormone Receptor-Positive Breast Cancer, Desmoid Tumors, Gynecologic Tumors, or Other Hormone Receptor-Positive Solid Tumors Active, not recruiting NCT01273168 Phase 1 Z-Endoxifen
32 Peripheral Primitive Fibromatosis. Study Evaluating a Simple Initial Monitoring With Search of Scalability Predictive Factors and Registration of Treatments in Case of Progression Unknown status NCT01801176
33 Tailored Beta-catenin Mutational Approach in Extra-abdominal Sporadic Desmoids Tumor Patients Unknown status NCT02547831
34 Role of Doppler Ultrasound in Evaluation of Superficial Soft Tissue Masses Unknown status NCT03171857
35 Does Fibrosis Diathesis Influence the Recovery of Knee Mobility After Total Knee Replacement? Unknown status NCT02294890
36 Genes Associated With Hereditary and Drug-Induced Gingival Overgrowth Completed NCT00104026
37 In Modern Era, Recurrent Desmoids Determine Outcome in Patients With Gardner Syndrome: A Cohort Study of Three Generations of an Adenomatous Polyposis Coli (APC-) Mutation-Positive Family Across 30 Years Completed NCT01286662
38 Evaluation of the Cryodestruction of Non Abdominopelvic Desmoid Tumors in Patients Progressing Despite Medical Completed NCT02476305
39 Sentinel Lymph Node Biopsy in Porocarcinoma: A Case Reports Completed NCT03647631
40 Biomarker for Hyaline Fibromatosis Syndrome - An International, Multicenter, Epidemiological Protocol Recruiting NCT03196115
41 Optional Sub-study to Intraoperative Imaging With ICG Registry Recruiting NCT02651246
42 National Clinical-biological Prospective Cohort of Incident Cases of Aggressive Fibromatosis Recruiting NCT02867033
43 The Project: EveryChild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study Recruiting NCT02402244
44 Natural Disease Progress of Dupuytren Disease Active, not recruiting NCT01923103
45 A COG Soft Tissue Sarcoma Diagnosis, Biology and Banking Protocol Active, not recruiting NCT00919269
46 Effect of Pulsed Radiofrequency to the Suprascapular Nerve in Treating Frozen Shoulder Pain Not yet recruiting NCT03456531 NSAIDs "ibubrofen,Aspirin"
47 Compassionate Use Protocol for PF-03084014 in Patients With Advanced Solid Tumor Malignancies: Continuing Study Drug Administration in Desmoid Patients Receiving Clinical Benefit No longer available NCT02955446 PF-03084014
48 Pilot Investigation of 18F-FES PET/CT Imaging of Desmoid Tumors Terminated NCT02374931 Early Phase 1 F-18 16 Alpha-Fluoroestradiol

Search NIH Clinical Center for Fibromatosis

Genetic Tests for Fibromatosis

Anatomical Context for Fibromatosis

MalaCards organs/tissues related to Fibromatosis:

40
Breast, Bone, Skin, Thyroid, Tongue, Colon, Pituitary

Publications for Fibromatosis

Articles related to Fibromatosis:

(show top 50) (show all 3416)
# Title Authors PMID Year
1
Paratesticular fibrous pseudotumor: a morphologic and immunohistochemical study of 13 cases. 54 61
20216379 2010
2
[Gardner fibroma: case report and discussion of a new soft tissue tumor entity]. 54 61
20063100 2010
3
High frequency of beta-catenin heterozygous mutations in extra-abdominal fibromatosis: a potential molecular tool for disease management. 54 61
20197769 2010
4
Prognostic factors in desmoid-type fibromatosis: a clinicopathological and immunohistochemical analysis of 46 cases. 54 61
20085516 2010
5
[Expression of beta-catenin and estrogen receptor in desmoid-type fibromatosis]. 54 61
20369480 2010
6
Beta-catenin expression in pediatric fibroblastic and myofibroblastic lesions: a study of 100 cases. 54 61
18939887 2009
7
Systemic hyalinosis mutations in the CMG2 ectodomain leading to loss of function through retention in the endoplasmic reticulum. 54 61
19191226 2009
8
Pediatric aggressive fibromatosis of the head and neck: a 20-year retrospective review. 54 61
18778992 2008
9
Beta-catenin mutations do not contribute to cardiac fibroma pathogenesis. 54 61
18078366 2008
10
Immunohistochemistry for beta-catenin in the differential diagnosis of spindle cell lesions: analysis of a series and review of the literature. 54 61
17711447 2007
11
Detection of beta-catenin mutations in paraffin-embedded sporadic desmoid-type fibromatosis by mutation-specific restriction enzyme digestion (MSRED): an ancillary diagnostic tool. 54 61
17721184 2007
12
Characterization of the interaction between anthrax toxin and its cellular receptors. 54 61
17381430 2007
13
Preoperative treatment of uterine leiomyomas: clinical findings and expression of transforming growth factor-beta3 and connective tissue growth factor. 54 61
16697947 2006
14
[Clonality study of palmar fibromatosis]. 54 61
16776980 2006
15
Differential expression of smooth muscle myosin, smooth muscle actin, h-caldesmon, and calponin in the diagnosis of myofibroblastic and smooth muscle lesions of skin and soft tissue. 54 61
16625070 2006
16
L1 (CD171) is highly expressed in gastrointestinal stromal tumors. 54 61
16400320 2006
17
Desmoplastic fibroma of bone: an immunohistochemical study including beta-catenin expression and mutational analysis for beta-catenin. 54 61
16153468 2005
18
Nuclear beta-catenin expression distinguishes deep fibromatosis from other benign and malignant fibroblastic and myofibroblastic lesions. 54 61
15832090 2005
19
Nuclear beta-catenin in mesenchymal tumors. 54 61
15375433 2005
20
Response of estrogen receptor-positive intraabdominal fibromatosis to aromatase inhibitor therapy. 54 61
14607040 2003
21
Matrix metalloproteinases and tissue inhibitors of metalloproteinases in sera and tissue of patients with Dupuytren's disease. 54 61
14504511 2003
22
An immunohistochemical study of metaplastic spindle cell carcinoma, phyllodes tumor and fibromatosis of the breast. 54 61
14608534 2003
23
Beta-catenin expression in Dupuytren's disease: potential role for cell-matrix interactions in modulating beta-catenin levels in vivo and in vitro. 54 61
12802275 2003
24
[Immunohistochemical differentiation of leiomyocellular tumors and tumors with myogenic differentiation]. 54 61
12874903 2003
25
Beta-catenin immunohistochemistry separates mesenteric fibromatosis from gastrointestinal stromal tumor and sclerosing mesenteritis. 54 61
12360044 2002
26
Fibromatosis of the breast and mutations involving the APC/beta-catenin pathway. 54 61
11823972 2002
27
Superficial fibromatoses are genetically distinct from deep fibromatoses. 54 61
11455002 2001
28
Primary fibromatosis of the breast in a patient with multiple desmoid tumors--report of a case with evaluation of estrogen and progesterone receptors. 54 61
11770022 2001
29
Fibromatosis of the breast: age-correlated morphofunctional features of 33 cases. 54 61
10656738 2000
30
APC and beta-catenin in alveolar soft part sarcoma (ASPS)--immunohistochemical and molecular genetic analysis. 54 61
10834386 2000
31
Familial infiltrative fibromatosis (desmoid tumours) (MIM135290) caused by a recurrent 3' APC gene mutation. 54 61
8968744 1996
32
TGF beta and bFGF synthesis and localization in Dupuytren's disease (nodular palmar fibromatosis) relative to cellular activity, myofibroblast phenotype and oncofetal variants of fibronectin. 54 61
8789403 1995
33
Differential expression of fibronectin splice variants, oncofetal glycosylated fibronectin and laminin isoforms in nodular palmar fibromatosis. 54 61
8822112 1995
34
Oestrogen and progesterone receptor expression in mammary fibromatosis. 54 61
8496393 1993
35
Infantile digital fibromatosis. Immunohistochemical and immunoelectron microscopic studies. 54 61
1697612 1990
36
Activation of CncC pathway by ROS burst regulates cytochrome P450 CYP6AB12 responsible for λ-cyhalothrin tolerance in Spodoptera litura. 61
31791865 2020
37
Understanding the histogenesis of a HRAS-PIK3R1 co-driven metastatic metaplastic breast carcinoma associated with squamous metaplasia of lactiferous ducts. 61
31867792 2020
38
Anesthetic Management of an Adult Patient With Hyaline Fibromatosis Syndrome Undergoing Laparoscopic Colectomy: A Case Report. 61
31842195 2020
39
[Hereditary gingival fibromatosis: a three-generation case report]. 61
32037776 2020
40
Non-malignant fibroblastic/myofibroblastic tumors in pediatric age group: Clues and pitfalls to the cytological diagnosis. 61
32034815 2020
41
Prospective development of a patient-reported outcomes instrument for desmoid tumors or aggressive fibromatosis. 61
31691276 2020
42
Juvenile Hyaline Fibromatosis. 61
32029086 2020
43
Evidence-based MR imaging follow-up strategy for desmoid-type fibromatosis. 61
31468156 2020
44
Fibromatosis Colli: A Case Report. 61
32000186 2020
45
Soft Tissue Special Issue: Fibroblastic and Myofibroblastic Neoplasms of the Head and Neck. 61
31950474 2020
46
[Resection of soft tissue tumours : Pitfalls, typical complications and prevention strategies]. 61
31974631 2020
47
Gingival fibromatosis with congenital hypertrichosis. 61
31983850 2020
48
Generalized hereditary gingival fibromatosis in a child: clinical, histopathological and therapeutic aspects. 61
32039068 2020
49
[Imaging of extraabdominal aggressive fibromatosis]. 61
31994152 2020
50
Desmoid Fibromatosis of the Maxilla. 61
31937133 2020

Variations for Fibromatosis

Cosmic variations for Fibromatosis:

9
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM97107943 NRAS soft tissue,skin,sarcoma,NS c.38G>C p.G13A 1:114716123-114716123 3

Expression for Fibromatosis

Search GEO for disease gene expression data for Fibromatosis.

Pathways for Fibromatosis

Pathways related to Fibromatosis according to GeneCards Suite gene sharing:

(show all 15)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.28 SOS1 CTNNB1 ACTC1
2 11.85 SOS1 CTNNB1 APC
3 11.85 VIM REST CTNNB1 APC
4 11.73 REST CTNNB1 APC
5
Show member pathways
11.61 VIM CTNNB1 APC
6 11.56 SOS1 CTNNB1 APC
7 11.48 SOS1 CTNNB1 APC
8 11.17 CTNNB1 APC
9 11.13 CTNNB1 ACTC1
10 11.02 VIM CTNNB1
11 10.99 VIM DES ACTC1
12 10.97 CTNNB1 APC
13 10.86 CTNNB1 APC
14 10.69 CTNNB1 APC
15 10.63 SOS1 CTNNB1 APC

GO Terms for Fibromatosis

Cellular components related to Fibromatosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytosol GO:0005829 10.01 VIM SOS1 SAMD9 REST DES CTNNB1
2 cytoskeleton GO:0005856 9.77 VIM DES CTNNB1 APC ACTC1
3 lamellipodium GO:0030027 9.43 CTNNB1 APC ACTC1
4 catenin complex GO:0016342 9.32 CTNNB1 APC
5 beta-catenin destruction complex GO:0030877 9.16 CTNNB1 APC
6 Wnt signalosome GO:1990909 8.96 CTNNB1 APC
7 fascia adherens GO:0005916 8.62 DES CTNNB1

Biological processes related to Fibromatosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of cell differentiation GO:0045595 9.48 CTNNB1 APC
2 cell fate specification GO:0001708 9.46 CTNNB1 APC
3 negative regulation of neurogenesis GO:0050768 9.43 REST CTNNB1
4 beta-catenin destruction complex disassembly GO:1904886 9.4 CTNNB1 APC
5 intermediate filament organization GO:0045109 9.37 VIM DES
6 negative regulation of oxidative stress-induced neuron death GO:1903204 9.32 REST CTNNB1
7 regulation of osteoblast differentiation GO:0045667 9.26 REST CTNNB1
8 positive regulation of apoptotic process GO:0043065 9.26 SOS1 REST CTNNB1 APC
9 regulation of T cell proliferation GO:0042129 9.16 SOS1 CTNNB1
10 muscle filament sliding GO:0030049 8.8 VIM DES ACTC1

Sources for Fibromatosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....